JP6491656B2 - 新規アザベンズイミダゾール誘導体 - Google Patents
新規アザベンズイミダゾール誘導体 Download PDFInfo
- Publication number
- JP6491656B2 JP6491656B2 JP2016526557A JP2016526557A JP6491656B2 JP 6491656 B2 JP6491656 B2 JP 6491656B2 JP 2016526557 A JP2016526557 A JP 2016526557A JP 2016526557 A JP2016526557 A JP 2016526557A JP 6491656 B2 JP6491656 B2 JP 6491656B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- pyridin
- imidazo
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCc(nc1[n]2*)c(*)cc1nc2O* Chemical compound CCCc(nc1[n]2*)c(*)cc1nc2O* 0.000 description 9
- MIGCASOTMSNJLO-CDRKEARJSA-N CCCN(CCC)c(cc1)ccc1-c(nc1[n](COCC[SiH-](C)(C)C)c(O[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc1c1)c1Cl Chemical compound CCCN(CCC)c(cc1)ccc1-c(nc1[n](COCC[SiH-](C)(C)C)c(O[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc1c1)c1Cl MIGCASOTMSNJLO-CDRKEARJSA-N 0.000 description 1
- URFHSXXJRVBXEM-UHFFFAOYSA-N CN=S1(CC(CNC2)C2C1)=O Chemical compound CN=S1(CC(CNC2)C2C1)=O URFHSXXJRVBXEM-UHFFFAOYSA-N 0.000 description 1
- QLMHBBHJAIQYGG-UHFFFAOYSA-N CS(OCC1C(COS(C)(=O)=O)CN(Cc2ccccc2)C1)(=O)=O Chemical compound CS(OCC1C(COS(C)(=O)=O)CN(Cc2ccccc2)C1)(=O)=O QLMHBBHJAIQYGG-UHFFFAOYSA-N 0.000 description 1
- CGNTUXJRYTWXLO-TWMQYOFOSA-N CS(c1cc(-c(cc2)ccc2-c(nc2[nH]c(O[C@H](CO[C@@H]34)[C@H]3OC[C@H]4O)nc2c2)c2Cl)ccc1)(=N)=O Chemical compound CS(c1cc(-c(cc2)ccc2-c(nc2[nH]c(O[C@H](CO[C@@H]34)[C@H]3OC[C@H]4O)nc2c2)c2Cl)ccc1)(=N)=O CGNTUXJRYTWXLO-TWMQYOFOSA-N 0.000 description 1
- LDFHUSHZIQAFLU-UHFFFAOYSA-N C[Si+](C)(C)CCOC[n](c1n2)c(S(C)(=O)=O)nc1cc(Cl)c2I Chemical compound C[Si+](C)(C)CCOC[n](c1n2)c(S(C)(=O)=O)nc1cc(Cl)c2I LDFHUSHZIQAFLU-UHFFFAOYSA-N 0.000 description 1
- LUKJSRYUAZFSJD-AAVRWANBSA-N C[Si+](C)CCOC[n](c1n2)c(O[C@H](CO[C@@H]34)[C@H]3OC[C@H]4O)nc1cc(Cl)c2I Chemical compound C[Si+](C)CCOC[n](c1n2)c(O[C@H](CO[C@@H]34)[C@H]3OC[C@H]4O)nc1cc(Cl)c2I LUKJSRYUAZFSJD-AAVRWANBSA-N 0.000 description 1
- SGVIYBXEKKBQJO-BAWFOZSCSA-N C[SiH-](C)(C)CCOC[n]1c(OC(CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3C(O)=O)nc12 Chemical compound C[SiH-](C)(C)CCOC[n]1c(OC(CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3C(O)=O)nc12 SGVIYBXEKKBQJO-BAWFOZSCSA-N 0.000 description 1
- UYMVNJQIQWHLQF-CDRKEARJSA-N C[SiH-](C)(C)CCOC[n]1c(O[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3/C(/N)=[O]/CSC3CCOCC3)nc12 Chemical compound C[SiH-](C)(C)CCOC[n]1c(O[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3/C(/N)=[O]/CSC3CCOCC3)nc12 UYMVNJQIQWHLQF-CDRKEARJSA-N 0.000 description 1
- CYRLODKVDHTROF-UGESXGAOSA-N C[SiH-](C)(C)CCOC[n]1c(O[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3Br)nc12 Chemical compound C[SiH-](C)(C)CCOC[n]1c(O[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3Br)nc12 CYRLODKVDHTROF-UGESXGAOSA-N 0.000 description 1
- JIXKEIYDNOBBOB-OSBPIYGISA-N Cc1c(-c(cc2)ccc2-c(cc2)ccc2S(C)(=N)=O)nc2[nH]c(O[C@H](COC34)C3OC[C@H]4O)nc2c1 Chemical compound Cc1c(-c(cc2)ccc2-c(cc2)ccc2S(C)(=N)=O)nc2[nH]c(O[C@H](COC34)C3OC[C@H]4O)nc2c1 JIXKEIYDNOBBOB-OSBPIYGISA-N 0.000 description 1
- LNWSHKFYMZAHIP-OHUMZHCVSA-N Cc1c(-c(cc2)ccc2Br)nc2[n](COCC[SiH-](C)(C)C)c(O[C@H](CO[C@@H]34)[C@H]3OC[C@H]4O)nc2c1 Chemical compound Cc1c(-c(cc2)ccc2Br)nc2[n](COCC[SiH-](C)(C)C)c(O[C@H](CO[C@@H]34)[C@H]3OC[C@H]4O)nc2c1 LNWSHKFYMZAHIP-OHUMZHCVSA-N 0.000 description 1
- ZCWROQWEBAMYKH-UDCKCYQBSA-N Cc1c(-c(cc2)ccc2N(C2)Cc3c2ccc(N=S(C)(C)=O)c3)nc2[nH]c(O[C@H](CO[C@@H]34)[C@H]3OC[C@H]4O)nc2c1 Chemical compound Cc1c(-c(cc2)ccc2N(C2)Cc3c2ccc(N=S(C)(C)=O)c3)nc2[nH]c(O[C@H](CO[C@@H]34)[C@H]3OC[C@H]4O)nc2c1 ZCWROQWEBAMYKH-UDCKCYQBSA-N 0.000 description 1
- DEUDDXFIVAYVPA-UHFFFAOYSA-N N=S1(CC(CN(C2)C(OCc3ccccc3)=O)C2C1)=O Chemical compound N=S1(CC(CN(C2)C(OCc3ccccc3)=O)C2C1)=O DEUDDXFIVAYVPA-UHFFFAOYSA-N 0.000 description 1
- RGODGAZBAVISJP-UHFFFAOYSA-N O=C(N(C1)CC(C2)C1CS2(=NCC(F)(F)F)=O)OCc1ccccc1 Chemical compound O=C(N(C1)CC(C2)C1CS2(=NCC(F)(F)F)=O)OCc1ccccc1 RGODGAZBAVISJP-UHFFFAOYSA-N 0.000 description 1
- QIJDSFJFJYWEPU-UHFFFAOYSA-N O=C(N(C1)CC(C2)C1CS2=O)OCc1ccccc1 Chemical compound O=C(N(C1)CC(C2)C1CS2=O)OCc1ccccc1 QIJDSFJFJYWEPU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176929.1 | 2013-07-17 | ||
| EP13176929 | 2013-07-17 | ||
| PCT/EP2014/065004 WO2015007669A1 (en) | 2013-07-17 | 2014-07-14 | New azabenzimidazole derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527223A JP2016527223A (ja) | 2016-09-08 |
| JP2016527223A5 JP2016527223A5 (enExample) | 2017-07-20 |
| JP6491656B2 true JP6491656B2 (ja) | 2019-03-27 |
Family
ID=48790302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526557A Active JP6491656B2 (ja) | 2013-07-17 | 2014-07-14 | 新規アザベンズイミダゾール誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9492436B2 (enExample) |
| EP (1) | EP3022210B1 (enExample) |
| JP (1) | JP6491656B2 (enExample) |
| KR (1) | KR20160033749A (enExample) |
| CN (1) | CN105377857B (enExample) |
| AR (1) | AR096936A1 (enExample) |
| AU (1) | AU2014292236B2 (enExample) |
| CA (1) | CA2918401A1 (enExample) |
| CL (1) | CL2016000026A1 (enExample) |
| DK (1) | DK3022210T3 (enExample) |
| EA (1) | EA032195B1 (enExample) |
| ES (1) | ES2669543T3 (enExample) |
| HU (1) | HUE038261T2 (enExample) |
| MX (1) | MX359040B (enExample) |
| PH (1) | PH12016500092B1 (enExample) |
| PL (1) | PL3022210T3 (enExample) |
| TR (1) | TR201806860T4 (enExample) |
| TW (1) | TW201546076A (enExample) |
| UY (1) | UY35668A (enExample) |
| WO (1) | WO2015007669A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3180338B1 (en) * | 2014-08-11 | 2018-05-09 | Boehringer Ingelheim International GmbH | Azabenzimidazole derivatives as amp protein kinase agonistes |
| AU2015309863B2 (en) | 2014-08-27 | 2019-12-05 | Shionogi & Co., Ltd. | Azaindole derivative having AMPK-activating effect |
| KR20170077131A (ko) | 2014-10-28 | 2017-07-05 | 시오노기세야쿠 가부시키가이샤 | Ampk 활성화 작용을 갖는 복소환 유도체 |
| JP6612881B2 (ja) * | 2015-01-16 | 2019-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なアザベンゾイミダゾール誘導体 |
| JPWO2017146186A1 (ja) | 2016-02-26 | 2018-12-20 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有する５−フェニルアザインドール誘導体 |
| CN109476661A (zh) * | 2016-05-20 | 2019-03-15 | 盐野义制药株式会社 | 具有ampk活化作用的5-取代苯并咪唑及5-取代氮杂苯并咪唑衍生物 |
| WO2020080979A1 (en) * | 2018-10-15 | 2020-04-23 | Gero Discovery Limited Liability Company | Pfkfb3 inhibitors and their uses |
| UY38941A (es) | 2019-11-11 | 2021-06-30 | Pi Industries Ltd | Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| AU2024222719A1 (en) | 2023-02-16 | 2025-08-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008008887A2 (en) * | 2006-07-13 | 2008-01-17 | Smithkline Beecham Corporation | Gpr119 agonists for treating metabolic disorders |
| WO2012033149A1 (ja) | 2010-09-10 | 2012-03-15 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体 |
| PH12013501686A1 (en) * | 2011-02-25 | 2017-10-25 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| RU2015109706A (ru) * | 2012-08-22 | 2016-10-10 | Мерк Шарп И Доум Корп. | Новые производные азабензимидазол гексагидрофуро[3, 2-в]фурана |
| WO2014031468A1 (en) * | 2012-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | Novel benzimidazole hexahydrofuro[3,2-b]furan derivatives |
| WO2014069426A1 (ja) * | 2012-10-31 | 2014-05-08 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体 |
-
2014
- 2014-07-14 DK DK14738531.4T patent/DK3022210T3/en active
- 2014-07-14 ES ES14738531.4T patent/ES2669543T3/es active Active
- 2014-07-14 WO PCT/EP2014/065004 patent/WO2015007669A1/en not_active Ceased
- 2014-07-14 JP JP2016526557A patent/JP6491656B2/ja active Active
- 2014-07-14 PL PL14738531T patent/PL3022210T3/pl unknown
- 2014-07-14 TR TR2018/06860T patent/TR201806860T4/tr unknown
- 2014-07-14 KR KR1020167004147A patent/KR20160033749A/ko not_active Withdrawn
- 2014-07-14 CN CN201480040799.5A patent/CN105377857B/zh active Active
- 2014-07-14 MX MX2016000547A patent/MX359040B/es active IP Right Grant
- 2014-07-14 EP EP14738531.4A patent/EP3022210B1/en active Active
- 2014-07-14 AU AU2014292236A patent/AU2014292236B2/en not_active Ceased
- 2014-07-14 HU HUE14738531A patent/HUE038261T2/hu unknown
- 2014-07-14 EA EA201600113A patent/EA032195B1/ru not_active IP Right Cessation
- 2014-07-14 CA CA2918401A patent/CA2918401A1/en not_active Abandoned
- 2014-07-15 US US14/331,359 patent/US9492436B2/en active Active
- 2014-07-16 TW TW103124425A patent/TW201546076A/zh unknown
- 2014-07-16 AR ARP140102623A patent/AR096936A1/es unknown
- 2014-07-17 UY UY0001035668A patent/UY35668A/es unknown
-
2016
- 2016-01-07 CL CL2016000026A patent/CL2016000026A1/es unknown
- 2016-01-14 PH PH12016500092A patent/PH12016500092B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014292236A1 (en) | 2016-01-21 |
| CN105377857A (zh) | 2016-03-02 |
| CL2016000026A1 (es) | 2016-08-12 |
| MX359040B (es) | 2018-09-13 |
| ES2669543T3 (es) | 2018-05-28 |
| DK3022210T3 (en) | 2018-06-06 |
| EA201600113A1 (ru) | 2016-07-29 |
| TW201546076A (zh) | 2015-12-16 |
| US9492436B2 (en) | 2016-11-15 |
| TR201806860T4 (tr) | 2018-06-21 |
| JP2016527223A (ja) | 2016-09-08 |
| CA2918401A1 (en) | 2015-01-22 |
| PH12016500092B1 (en) | 2019-04-12 |
| KR20160033749A (ko) | 2016-03-28 |
| PL3022210T3 (pl) | 2018-08-31 |
| AU2014292236B2 (en) | 2018-11-08 |
| WO2015007669A1 (en) | 2015-01-22 |
| EP3022210B1 (en) | 2018-02-21 |
| MX2016000547A (es) | 2016-04-20 |
| US20150025065A1 (en) | 2015-01-22 |
| EP3022210A1 (en) | 2016-05-25 |
| HUE038261T2 (hu) | 2018-10-29 |
| CN105377857B (zh) | 2018-04-10 |
| AR096936A1 (es) | 2016-02-10 |
| EA032195B1 (ru) | 2019-04-30 |
| UY35668A (es) | 2015-01-30 |
| PH12016500092A1 (en) | 2016-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6491656B2 (ja) | 新規アザベンズイミダゾール誘導体 | |
| US20250115606A1 (en) | Heterocyclic glp-1 agonists | |
| JP6588966B2 (ja) | Ａｍｐタンパク質キナーゼ作動薬としてのアザベンゾイミダゾール誘導体 | |
| JP5301456B2 (ja) | ヘテロアリールオキシキナゾリン誘導体 | |
| EA022064B1 (ru) | Гетариламинонафтиридины в качестве ингибиторов атф-связывающих белков | |
| WO2018138027A1 (en) | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof | |
| JP6612881B2 (ja) | 新規なアザベンゾイミダゾール誘導体 | |
| JP6474804B2 (ja) | アザベンゾイミダゾール誘導体 | |
| TW201831476A (zh) | 吡啶并〔３，４－ｄ〕嘧啶衍生物及其藥學上所容許之鹽 | |
| JP2018502133A (ja) | Ａｍｐ活性化タンパク質キナーゼのアゴニストとしての新規アザベンゾイミダゾール誘導体 | |
| US8809361B2 (en) | 2,3-dihydrofuro[2,3-c]pyridines, their use as modulators of the G-protein-coupled receptor GPR119 and pharmaceutical compositions thereof | |
| JP2012501295A (ja) | オキソテトラヒドロフラン−２−イル−ベンズイミダゾール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170606 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180625 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180925 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190131 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190301 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6491656 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |